Lorient Capital, a healthcare-focused investment firm, announced it has successfully closed Lorient Healthcare Fund III with $500 million in commitments, surpassing its $350 million target. The fund, which closed on June 30th, was oversubscribed.
Lorient partners with founder-led, middle-market healthcare companies, using its sector expertise, operational capabilities, and a proprietary technology platform called Morpheus to scale businesses. The firm focuses on areas like consumer-directed healthcare, post-acute care, and behavioral health, aiming to improve clinical outcomes, workforce efficiency, and access to care.
Co-Managing Partners David Berman and Jordan Broome stated that Fund III reinforces Lorient’s mission to support companies that improve the healthcare system and create sustainable value, driving both strong returns and meaningful impact. Lorient has a track record of 20 platform investments and over 75 add-on acquisitions.
KEY QUOTES:
“Fund III represents a major step forward in our mission to support companies working to improve the healthcare system and create long-term, sustainable value. We’re deeply grateful to our existing partners for their continued support and to our new investors who share our conviction that healthcare investing can drive both strong returns and meaningful impact.”
David Berman and Jordan Broome, Co-Managing Partners at Lorient Capital
“Morpheus is our engine for accelerating transformation. It enables us to go beyond capital, embedding the tools, insights, and capabilities our portfolio companies need to scale effectively and deliver better care.”
Jordan Broome
